Oppenheimer Downgrades Dyne Therapeutics to Perform, Sets $15 Price Target
Oppenheimer cut its rating on Dyne Therapeutics to Perform from Outperform and set a $15 price target. Dyne has an average rating of buy, according to the report.
Related stories
Flexiroam Reports Q1 FY27 Revenue of A$2.04 Million
M impact | EQUITY | Oct 30, 2026, 01:33 AM UTC
Impedimed Posts Q1 Revenue of A$3.8 Million
M impact | EQUITY | Oct 30, 2026, 01:32 AM UTC
Eoptolink Tech Shares Fall More Than 11%
M impact | EQUITY | Oct 30, 2026, 01:32 AM UTC
DXN Posts Q1 FY27 Revenue of A$3.4 Million
DXN reported Q1 FY27 revenue of A$3.4 million.
M impact | EQUITY | Oct 30, 2026, 01:32 AM UTC
Shanghai Composite Falls Below 3,600 in Morning Trading
L impact | EQUITY | Oct 30, 2026, 01:31 AM UTC
Timberland Bancorp Q4 Earnings Snapshot
Timberland Bancorp reported net income for its fiscal fourth quarter.
M impact | EQUITY | Oct 30, 2026, 01:31 AM UTC